Last reviewed · How we verify
NCT07185646
Mechanistic Study of SPARC-Mediated Regulation of Neutrophil Extracellular Trap Formation in the Brain Metastatic Microenvironment of Breast Cancer
trial in Neuro-Oncology in 200 participants. Participants enrolled and being followed up; not accepting new ones.
30 December 2028
Quick facts
| Lead sponsor | Second Xiangya Hospital of Central South University |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 1 January 2023 |
| Primary completion | 30 December 2028 |
| Estimated completion | 30 December 2030 |
| Sites | 1 location across China |
Conditions studied
- Neuro-Oncology — all drugs for Neuro-Oncology →
- MRI Imaging — all drugs for MRI Imaging →
- Tumor Immune Microenvironment — all drugs for Tumor Immune Microenvironment →
Sponsor
Second Xiangya Hospital of Central South University
Who can join
Adults 18 to 80, any sex, with Neuro-Oncology or MRI Imaging. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of this observational study is to investigate the characteristics of the tumor microenvironment in patients with brain tumors using multi-modal magnetic resonance imaging (MRI). The primary research question it aims to address is: • Can multi-modal MRI effectively characterize features of the immune microenvironment in brain tumor patients? Participants: Eligible participants who have been diagnosed with a brain tumor will undergo multi-modal MRI scans for detailed assessment of tumor microenvironment features.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07185646
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Second Xiangya Hospital of Central South University trials
Trials by the same sponsor.
- NCT07278947 — ACT-based Parenting Program for Caregivers of Children With Hearing Loss Post-cochlear: A Pilot Randomised Controlled Tr · NA · not yet recruiting
- NCT07460336 — Effects of Cofrogliptin on Beta-Cell Function in LADA Patients · NA · not yet recruiting
- NCT06951646 — ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immuno · Phase 2 · recruiting
- NCT07343154 — Multimodal Brain Function in Migraine Patients With Patent Foramen Ovale · not yet recruiting
- NCT07338487 — A Clinical Study of Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Cervical Canc · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07185646 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Second Xiangya Hospital of Central South University
- Last refreshed: 23 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07185646.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing